Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term follow-up (LTFU) studies can last from 15 years to a lifetime. Cell and gene ...

Pfizer and BioNTech’s updated COVID-19 vaccine targeting the KP.2 strain, a descendant of JN.1, has been recommended by the ...

Wherever you sit in the partnership triangle, does it sound familiar? Many initiatives have tried to address this partnership ...

The US Food and Drug Administration (FDA) has approved Zevra Therapeutics’ Miplyffa (arimoclomol) to treat Niemann-Pick ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the European Commission (EC) to treat adults with ...

Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...

Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...

Picture this: a medicine targeting a particular disease is developed over 12-15 years from initial candidate selection, ...

The essence of omnichannel marketing is to ensure that your messaging is reaching your target audience where they spend most ...

The European Commission (EC) has extended the marketing authorisation for Bavarian Nordic’s smallpox and mpox vaccine to ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for certain cases of acute myeloid leukaemia (AML). The drug has been ...